Using ALK IHC to identify potential responders to ALK inhibitors outside of NSCLC


1Joanne Xiu, 1Zoran Gatalica, 1Brian L. Abbott, 1Sandeep K. Reddy, 2Ari M. Vanderwalde, 3Fadi S. Braiteh

Background: In addition to anaplastic lymphomas and Non-Small Cell Lung Cancer (NSCLC), other solid malignancies can exhibit aberration in ALK expression potentially amenable to benefit from TKI ALK inhibitors. ALK expression by immunohistochemistry (IHC) has been extensively studied in NSCLC as a cost-effective and accurate screening tool for ALK rearrangement, and may identify patients (pts) with other mechanisms of ALK over-expression; however it has not been systematically studied outside of NSCLC.

Download Publication